Phase 3Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrolment
- 586 planned
- Conditions
- Alzheimer's Disease
- Interventions
- KarXT; KarX-EC; Placebo
- Ages
- adults, older adults
- Registry
- NCT06976216
From the registry
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Primary outcomes
- Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
- Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)